Connecticut-based firm Biohaven has said its migraine drug rimegepant showed superiority over placebo in a Phase 3 clinical trial.
The calcitonin gene-related peptide (CGRP) receptor antagonist was successful in relieving pain in patients with migraine in a Phase 3 trial, the results of which are published in the New England Journal of Medicine (NEJM).
